Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

Histrelin (Supprelin LA; Vantas discontinued): what the evidence says

Name: Histrelin (Supprelin LA; Vantas discontinued)
Published: 2026-10-27

At a glance

What it is: a synthetic 9-amino-acid GnRH analog released from a small implant placed under the skin of the upper arm. Approved as Supprelin LA (May 2007) for central precocious puberty in children. A version for prostate cancer (Vantas) was also approved but is now listed as discontinued. ^{R1, R2, R3}

What the evidence says: 🟨 in a single-arm trial of 36 children with central precocious puberty, the implant kept puberty hormones suppressed. ^R4 In men with prostate cancer, testosterone stayed suppressed in long-term open-label use. ^R5

Biggest risks: implant-site reactions were very common (51.1%); the label also warns about an early hormone surge, implant breakage, psychiatric events, seizures, severe skin reactions and raised pressure in the skull. Prohibited in male athletes. ^{R3, R6}

Rating


Human Human evidence	Moderate: single-arm trials plus long-term follow-up ^{R4, R5}
Animal Animal / lab evidence	Not reviewed
Regulatory	FDA-approved ^R1 · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page ^{R7, R8, R9} · prohibited in male athletes (WADA S2.2.1) ^R6
Established human dose	Yes, label dose (see Study details)

Evidence verdict: Central precocious puberty: Moderate (approved; single-arm trial) · Prostate cancer: Moderate (approved as Vantas, now discontinued) · Off-label hormone use: No human data

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

About the evidence: objective hormone endpoints, but no randomized comparisons in the trials reviewed.

What is it?

Related pages: goserelin, nafarelin, leuprolide, triptorelin.

Does it work?

🟨 Precocious puberty: LH suppressed in 36 children. ^R4
🟨 Prostate cancer (Vantas): testosterone suppressed through 4 years; hot flashes 64.4%. ^R5

Is it safe?

Implant-site reactions 51.1%. ^R3
Label warnings: initial flare, implant breakage, psychiatric events, convulsions, severe cutaneous reactions, pseudotumor cerebri. ^R3

Gray-market vials: extra risks

A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.

Is it legal?

US: FDA-approved, prescription (Supprelin LA). Vantas is listed as discontinued in openFDA. ^{R1, R2}
Compounding: not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. ^{R7, R8, R9}
Sport: prohibited at all times in male athletes; WADA names it among the GnRH analogues under S2.2.1. ^R6

Study details

These are amounts researchers used, not recommendations.

Study	People / model	Route	Amount used	Follow-up	Reported	Citation
Eugster 2007 (phase 3, open-label)	36 children with CPP	SC implant	Per label	12 months	LH suppressed	PMID 17327379
Shore 2012 (open-label extension)	104 men with advanced prostate cancer	SC implant	Per study	Up to 4+ years	Testosterone suppressed; hot flashes 64.4%	PMID 21851539

Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 27, 2026)

^R1 Drugs@FDA, Supprelin LA (histrelin), application NDA022058 (openFDA drugsfda record checked Oct 27, 2026). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA022058
^R2 Drugs@FDA, Vantas (histrelin), application NDA021732 (openFDA drugsfda record checked Oct 27, 2026). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA021732
^R3 Supprelin LA prescribing information, label published Sep 25, 2025 (DailyMed, checked Oct 27, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8fb000e-3cc9-4803-b71d-2cc597661977
^R4 Eugster EA, et al. J Clin Endocrinol Metab. 2007. PMID 17327379
^R5 Shore N, et al. BJU Int. 2012. PMID 21851539
^R6 WADA. The 2026 Prohibited List, S2.2.1, Chorionic Gonadotrophin and Luteinizing Hormone and their releasing factors, naming goserelin, histrelin and nafarelin among the GnRH analogues (prohibited in males). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
^R7 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
^R8 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
^R9 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Disclaimer

This page is for education and harm reduction, not medical advice or a recommendation to use Histrelin (Supprelin LA; Vantas discontinued). This is a prescription medicine. Use it only under the care of a licensed clinician; do not buy it from research-chemical or gray-market sellers. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).